High Cancer Drug Prices Hurt Patients

VBCC - February 2015, ASH 2014 Highlights - Health Economics
Kate Smith

San Francisco, CA—Hagop M. Kantarjian, MD, Professor and Chair of Leukemia, M.D. Anderson Cancer Center, Houston, TX, did not mince words during his talk at the ASH 2014 special session on drug pricing.

“Drug prices are definitely too high, and this is harming our patients….We need a situation where cancer drugs are affordable and patients can take them without the anxiety associated with lack of affordability,” Dr Kantarjian said.

Disputing the claim that rising prices is not a new concern, he pointed out that before 2000, the average cost of an oncology drug was less than $10,000 annually. Since then, prices have risen 10-fold, while the average household income has diminished by 8%. This disparity has compromised the financial and emotional security of many patients with cancer, whose out-of-pocket expenses are simply unaffordable, Dr Kantarjian said.

The end result, he suggested, is a “medical Darwinian system” in which “if you can pay, you live, and if you cannot, you may die from your disease.”

Although the concept of cost-sharing (ie, giving patients “skin in the game”) aims to facilitate value-based treatment choices, this holds true only for less expensive drugs and generics, and is not applicable to most cancer treatments, Dr Kantarjian said.

“In cancer, new drugs are patented, and patients don’t have this choice. Having skin in the game is only harmful to them,” he said.

Rebutting Common Arguments

Dr Kantarjian took exception to the arguments made to support high prices: that prices reflect the high cost of research and the cost–benefit ratio of the drug, that market forces will set prices at reasonable levels, and that price control will stifle innovation. “None of these are true, morally justifiable, or defensible,” Dr Kantarjian maintains.

He took exception to the argument that price reflects benefit, noting that some drugs prolong life by years and others by days, yet the near-universal annual cost of new agents is approximately $100,000. Market forces cannot correct price imbalances, he says, because drug companies do not compete on the basis of cost. In addition, drug companies set their own prices for the Medicare system.

Although manufacturers indicate that they set prices by calculating cost–­benefit ratio, examining the competitive marketplace, and estimating the potential market for the drug, Dr Kantarjian suggests that “companies look at the price of an existing drug and put a 20% higher price tag on the new one.”

“Making progress in drug development in the long run is not a reason to increase prices to a profiteering level,” he concluded.

Related Items
Increased Use of Sodium Channel Blockers May Reduce Costs in Partial-Onset Seizures
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
Parameters Affecting Treatment Decisions for Patients with Multiple Sclerosis
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
Unemployment Status Linked to Disability in Secondary-Progressive Multiple Sclerosis
Chase Doyle
VBCN - July 2015 Volume 2, No 2 published on August 5, 2015 in Health Economics
High Out-of-Pocket Cost of Biologic DMARDs Under Medicare Part D
Rosemary Frei, MSc
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Health Economics
Experts Make the Case for Putting Social Values Into Cost-Effectiveness Analyses
Rosemary Frei, MSc
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Health Economics
Mathematical Model Suggests It Is Cost-Effective to Combine Bariatric Surgery and Hip Replacement in Morbidly Obese Individuals
Rosemary Frei, MSc
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Health Economics
Prescription Drug Cost Sharing Parsed by Panel at Pharmacoeconomics Meeting
Rosemary Frei, MSc
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Health Economics
Preventing Disease Relapse in Patients with Multiple Sclerosis May Reduce Associated Costs
Chase Doyle
VBCN - May 2015 Volume 2, No 1 published on June 1, 2015 in Health Economics
Inpatient Care Coordination Could Impact Clinical Outcomes, Duration of Hospital Stays
Chase Doyle
VBCN - May 2015 Volume 2, No 1 published on June 1, 2015 in Health Economics
Inpatient Costs for MS-Related Disease Relapse Higher for Males Than for Females
Chase Doyle
VBCN - May 2015 Volume 2, No 1 published on June 1, 2015 in Health Economics
Last modified: February 26, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology